A Cost-Effective Rabbit Embolic Stroke Bioassay: Insight into the Development of Acute Ischemic Stroke Therapy

Translational Stroke Research

Volumn 6, Issue 2, 2015, Pages 99-103

  Lapchak, Paul A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

BIOASSAY; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; COST EFFECTIVENESS ANALYSIS; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NONHUMAN; PRIORITY JOURNAL; RABBIT EMBOLIC STROKE BIOASSAY; RANKIN SCALE; ANIMAL; COMPLICATION; COST BENEFIT ANALYSIS; DISEASE MODEL; PROCEDURES; RABBIT; STROKE;

ANIMALS; BIOLOGICAL ASSAY; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; RABBITS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84925482912     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-015-0386-x     Document Type: Editorial

References (75)

1. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61(1):46–55.
2. Pan Y, Chen Q, Zhao X, Liao X, Wang C, Du W, et al. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. PLoS ONE. 2014;9(10):e110525.
3. Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45(10):3032–9.
4. del Zoppo G. Thrombolytic therapy in cerebrovascular disease. Curr Concepts Cereb Dis. 1988;23:7.
5. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245–51.
6. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs. 2002;11(11):1623–32.
7. Lapchak PA, Araujo DM, Zivin JA. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185(1):154–9.
8. Lyden PD. Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms? Nat Clin Pract Cardiovasc Med. 2006;3(4):184–5.
9. Lyden PD, Lees KR, Davis SM. Alteplase for acute stroke revisited: the first 10 years. Lancet Neurol. 2006;5(9):722–4.
10. Lyden PD, Zivin JA, Clark WA, Madden K, Sasse KC, Mazzarella VA, et al. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology. 1989;39:703.
11. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74.
12. Hacke W, editor Thrombolysis, Thrombectomy and Acute Stroke Therapy Conference. Thrombolysis, Thrombectomy and Acute Stroke Therapy Conference; 2014; Heidelberg - Mannheim.
13. Lyden P, Lapchak P. Sisyphus and translational stroke research. Sci Transl Med. 2012;4(156):156ps20.
14. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985;230(4731):1289.
15. Zivin JA, Simmons J. tPA for stroke: the story of a controversial drug. New York: Oxford University Press; 2011. xiv, 191 p. p.
16. Lapchak PA, Zhang JH. Translational stroke research: from target selection to clinical trials. New York: Springer; 2012. xxiv, 923 p. p.
17. Lyden PD. Thrombolytic therapy for acute stroke. 2nd ed. Totowa, N.J: Humana Press; 2005. xvii, 370 p. p.
18. Lyden PD. Thrombolytic therapy for stroke. Totowa, N.J: Humana Press; 2001. xiv, 410 p. p.
19. Lyden PD. Thrombolytic therapy for acute stroke. New York: Springer; 2014. pages cm p.
20. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2):96–107.
21. Lapchak PA. A clinically relevant rabbit embolic stroke model for acute ischemic stroke therapy development: mechanisms & targets. In: Lapchak PA, Zhang JH, editors. Translational Stroke Research: From Target Selection to Clinical Trials. USA: Springer; 2012. p. 541–84.
22. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467–77.
23. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.
24. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–91.
25. Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841–3.
26. Kawaguchi M, Furuya H, Patel PM. Neuroprotective effects of anesthetic agents. J Anesth. 2005;19(2):150–6.
27. Sanders RD, Ma D, Maze M. Anaesthesia induced neuroprotection. Best Pract Res Clin Anaesthesiol. 2005;19(3):461–74.
28. Head BP, Patel P. Anesthetics and brain protection. Curr Opin Anaesthesiol. 2007;20(5):395–9.
29. Schifilliti D, Grasso G, Conti A, Fodale V. Anaesthetic-related neuroprotection: intravenous or inhalational agents? CNS Drugs. 2010;24(11):893–907.
30. Wei H, Inan S. Dual effects of neuroprotection and neurotoxicity by general anesthetics: role of intracellular calcium homeostasis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:156–61.
31. Combes RD. A critical review of anaesthetised animal models and alternatives for military research, testing and training, with a focus on blast damage, haemorrhage and resuscitation. Altern Lab Anim: ATLA. 2013;41(5):385–415.
32. Burchell SR, Dixon BJ, Tang J, Zhang JH. Isoflurane provides neuroprotection in neonatal hypoxic ischemic brain injury. J Investig Med. 2013;61(7):1078–83.
33. Karmarkar SW, Bottum KM, Tischkau SA. Considerations for the use of anesthetics in neurotoxicity studies. Comp Med. 2010;60(4):256–62.
34. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391–7.
35. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181–98.
36. Lapchak PA, Wei J, Zivin JA. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke. 2004;35(8):1985–8.
37. Zivin JA, Waud DR. Quantal bioassay and stroke. Stroke. 1992;23(5):767–73.
38. Lyden P, Pereira B, Chen B, Zhao L, Lamb J, Lei IF, et al. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. Stroke. 2014;45(3):896–9.
39. Lapchak PA, Chapman DF, Nunez SY, Zivin JA. Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA (A) receptors. Stroke. 2000;31:1953–6.
40. Turner R, Jickling G, Sharp F. Are underlying assumptions of current animal models of human stroke correct: from STAIRS to high hurdles? Transl Stroke Res. 2011;2(2):138–43.
41. Jickling GC, Sharp FR. Improving the translation of animal ischemic stroke studies to humans. Metab Brain Dis. 2014.
42. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.
43. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39(6):1751–8.
44. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6):588–600.
45. Hacke W, Schellinger PD, Albers GW, Bornstein NM, Dahlof BL, Fulton R, et al. Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial. Stroke. 2014;45(11):3187–93.
46. Patel R, Ispoglou S, Apostolakis S. Desmoteplase as a potential treatment for cerebral ischaemia. Expert Opin Investig Drugs. 2014;23(6):865–73.
47. Piechowski-Jozwiak B, Bogousslavsky J. The use of desmoteplase (bat saliva) in the treatment of ischaemia. Expert Opin Biol Ther. 2013;13(3):447–53.
48. von Kummer R, Albers GW, Mori E, Committees DS. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke. 2012;7(7):589–96.
49. Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. Expert Opin Biol Ther. 2009;9(6):773–8.
50. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25(11):2220–6.
51. Waud DR. On biological assays involving quantal responses. J Pharmacol Exp Ther. 1972;183(3):577–607.
52. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.
53. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11(10):1753–63.
54. Lapchak PA. Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model. Brain Res. 2009;1294:211–7.
55. Lapchak PA, Song D, Wei J, Zivin JA. Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence. Exp Neurol. 2004;188(2):286–91.
56. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145–50.
57. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002;2(1):38–43.
58. Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007;12(1):97–112.
59. Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs. 2007;12(3):389–406.
60. Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke. 1990;21(11):1589–93.
61. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5(1):1–16.
62. Lyden PD, Zivin JA, Soll M, Sitzer M, Rothrock JF, Alksne J. Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. Arch Neurol. 1987;44(8):848–50.
63. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31(12):3034–40.
64. Fagan SC, Lapchak PA, Liebeskind DS, Ishrat T, Ergul A. Recommendations for preclinical research in hemorrhagic transformation. Transl Stroke Res. 2013;4(3):322–7.
65. Levine SR, Hill MD. NeuroThera Effectiveness and Safety Trial 3: how do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly? Stroke. 2014;45(11):3175–7.
66. Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3):279–85.
67. Lapchak PA. Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Transl Stroke Res. 2013;4(3):328–42.
68. Keep RF, Wang MM, Xiang J, Hua Y, Xi G. Full steam ahead with remote ischemic conditioning for stroke. Transl Stroke Res. 2014;5(5):535–7.
69. Liu X, Zhao S, Liu F, Kang J, Xiao A, Li F, et al. Remote ischemic postconditioning alleviates cerebral ischemic injury by attenuating endoplasmic reticulum stress-mediated apoptosis. Transl Stroke Res. 2014;5(6):692–700.
70. Bahjat FR, Gesuete R, Stenzel-Poore MP. Steps to translate preconditioning from basic research to the clinic. Transl Stroke Res. 2013;4(1):89–103.
71. Tajiri N, Dailey T, Metcalf C, Mosley YI, Lau T, Staples M, et al. In vivo animal stroke models: a rationale for rodent and non-human primate models. Transl Stroke Res. 2013;4(3):308–21.
72. Rosell A, Agin V, Rahman M, Morancho A, Ali C, Koistinaho J, et al. Distal occlusion of the middle cerebral artery in mice: are we ready to assess long-term functional outcome? Transl Stroke Res. 2013;4(3):297–307.
73. Kristian T, Hu B. Guidelines for using mouse global cerebral ischemia models. Transl Stroke Res. 2013;4(3):343–50.
74. Nobile CW, Palmateer JM, Kane J, Hurn PD, Schallert T, Adkins DL. Impaired limb reaction to displacement of center of gravity in rats with unilateral striatal ischemic injury. Transl Stroke Res. 2014;5(5):562–8.
75. Kunze A, Zierath D, Drogomiretskiy O, Becker K. Variation in behavioral deficits and patterns of recovery after stroke among different rat strains. Transl Stroke Res. 2014;5(5):569–76.